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plus EBRT compared with
EBRT alone had a worse
ability to reach an orgasm,
erection quality, and ability
to function sexually. How-
ever, differences in the abil-
ity to have an erection,
frequency of erections, sex-
ual function, hot flashes,
breast tenderness, depres-
sion, lack of energy, and
body weight did not reach
statistical significance.
Purpose: The long-term effects of neoadjuvant androgen deprivation therapy (NADT)
with radiation therapy on participant-reported health-related quality of life (HRQOL)
have not been characterized in prospective multicenter studies. We evaluated HRQOL
for 2 years among participants undergoing radiation therapy (RT) with or without
NADT for newly diagnosed, early-stage prostate cancer.
Methods and Materials: We analyzed longitudinal cohort data from the Prostate Can-
cer Outcomes and Satisfaction with Treatment Quality Assessment Consortium to
ascertain the HRQOL trajectory of men receiving NADT with external beam RT
(EBRT) or brachytherapy. HRQOL was measured using the expanded prostate cancer
index composite 26-item questionnaire at 2, 6, 12, and 24 months after the initiation of
NADT. We used the c2 or Fisher exact test to compare the shift in percentages be-
tween groups that did or did not receive NADT. Analyses were conducted at the
2-sided 5% significance level.
Results: For subjects receiving EBRT, questions regarding the ability to have an erec-
tion, ability to reach an orgasm, quality of erections, frequency of erections, ability to
function sexually, and lack of energywere in a significantlyworse dichotomized category
for the patients receiving NADT. Comparing the baseline versus 24-month outcomes,
24%, 23%, and 30% of participants receiving EBRT plus NADT shifted to the worse
dichotomized category for the ability to reach an orgasm, quality of erections, and ability
to function sexually comparedwith 14%, 13%, and 16% in theEBRTgroup, respectively.
Conclusions: Compared with baseline, at 2 years, participants receiving NADT plus
EBRT compared with EBRT alone had worse HRQOL, as measured by the ability to
reach orgasm, quality of erections, and ability to function sexually. However, no differ-
ence was found in the ability to have an erection, frequency of erections, overall sexual
function, hot flashes, breast tenderness/enlargement, depression, lack of energy, or
change in body weight. The improved survival in intermediate- and high-risk patients
receiving NADT and EBRT necessitates pretreatment counseling of the HRQOL effect
of NADT and EBRT.  2017 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
Androgen deprivation therapy (ADT) strategies play a
crucial role in the radiotherapeutic management of inter-
mediate- and high-risk prostate adenocarcinoma. The addi-
tion of short-term and long-term ADT to radiation therapy
(RT), respectively, has improved overall and cancer-specific
survival in multiple randomized trials (1-8). Despite its
benefits, ADT has a number of potential side effects,
including sexual dysfunction (9), osteoporosis and bone
fractures (10), vasomotor symptoms (hot flashes) (11),
decreasedmuscle and increased fat (12), fatigue (13), anemia
(14), and thromboembolic events (15), among others. How-
ever, a systematic evaluation of health-related quality of life
(HRQOL) has not been a component of most of these trials.
The time course and severity of ADT side effects
in men receiving definitive RT for prostate cancer
has not been extensively characterized using validated,
participant-reported HRQOL instruments. A recent report
from the PROST-QA (Prostate Cancer Outcomes and
Satisfaction with Treatment Quality Assessment) con-
sortium focused on the short-term (2-month) effects of
neoadjuvant ADT (NADT) (16). In the present study, we
compared the HRQOL outcomes over time in men
receiving external beam RT (EBRT) or brachytherapy (BT)
with or without NADT.
Methods and Materials
Centers and subjects
We analyzed the longitudinal cohort data from the PROST-
QA consortium, a multi-institutional prospective study
conducted at 9 university-affiliated clinical sites across the
United States. Participants with early-stage (stage T1 or T2)
prostate cancer were recruited from 2003 to 2006 (17). The
institutional review boards approved the study, which was
judged compliant with the Health Insurance Portability and
Accountability Act at each center. Participants were ineli-
gible for the study if they had received any previous therapy
for prostate cancer. All participants provided written,
informed consent to participate.
In the PROST-QA trial, primary treatment could consist
of radical prostatectomy, EBRT, or BT. The selection of the
primary treatment modality was left to the discretion of the
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treating physician and the participant. At the present anal-
ysis, 1201 men with localized prostate cancer had been
registered to the PROST-QA study. Of these 1201 men, 603
(50.2%) had elected to undergo radical prostatectomy, 5
(0.42%) had undergone >12 months of NADT, 288
(24.0%) had received EBRT, 285 (23.7%) had received BT,
and another 20 (1.7%) had received a combination of EBRT
with a BT boost or ADT, or both.
The decision to administer NADTwas left to the treating
physician and typically started 2 months before the initia-
tion of RT. We decided to focus the present analysis on the
participants who had undergone definitive EBRT or BT
monotherapy with or without NADT for 12 months. In
the BT plus NADT group, the median ADT duration was
4 months (range 1-8), and in the EBRT plus NADT group,
the median ADT duration was 3 months (range 1-12).
Specifically, 202 participants received EBRT only, 86
received EBRT plus NADT, 271 received BT only, and 14
received BT plus NADT. NADT consisted of luteinizing
hormone-releasing hormone agonists and/or antiandrogens.
Two patients in the EBRT plus NADT group and four in the
BT plus NADT group received antiandrogens only. Of the
patients receiving EBRT plus NADT or BT plus NADT,
79% and 91% had received <6 months of NADT,
respectively.
Measures
At registration, the pretreatment demographics, cancer
severity, and treatment details were recorded. HRQOL was
measured using the expanded prostate cancer index com-
posite 26-item (EPIC-26) instrument self-reported by
computer-assisted telephone interviews before NADT and
at 2, 6, 12, and 24 months after NADT. The EPIC 26-item
questionnaire has been validated (18) and measures prostate
cancer-specific HRQOL (19) in men with early- and
advanced-stage prostate cancer. The questionnaire consists
of 4 summary domains (urinary, bowel, sexual, and vitality/
hormonal) and 2 urinary subscales (incontinence and irri-
tative/obstructive). Each summary domain contains func-
tion and bother subscales. The participants’ responses to
questions are transformed to a 0 to 100 scale, for which
higher scores represent better HRQOL. Norman et al (20)
defined a clinically meaningful change in function as a
change of greater than one half the standard deviation in an
HRQOL score.
Six questions in the sexual domain and five in vitality/
hormonal domain were analyzed. A previous study focused
on the short-term effects of ADT (16) at 2 months. In the
present study, we focused on the longer term responses at 6,
12, and 24 months.
Statistical analysis
The responses to the individual questions were dichoto-
mized (see Tables 2 and 4), thus combining 1 higher
severity items in 1 category and 1 items of less severity in
another the same as in the original report (17). For a given
treatment modality, the responses were further grouped
according to NADT or no NADT. The descriptive per-
centages of responses per group were reported according to
treatment modality: EBRT (see Tables 2 and 4) and BT (see
Tables 3 and 5). The power to detect an effect size of 0.5
using the sample size of 14 participants in the BT plus
NADT group and 271 participants in the BT group was
only 44.4%, with a type I error of 5%. The generalized
estimating equation (GEE) model was used to analyze the
longitudinal data, in which the correlation among the
repeated measures from the same participant are consid-
ered. The P values of the interaction term in the GEE model
were estimated to assess whether the percentages at each
measurement point between the no-NADT and NADT
groups were the same. The GEE model did not work for
some questions because of the small sample size; in those
cases, the Cochran-Mantel-Haenszel test was used. Missing
data were treated as missing at random and excluded from
the GEE analysis.
The percentage of difference for the participants who
shifted to the worse dichotomized category for a given
question was calculated for the baseline versus 24-month
and 6-month versus 24-month values (see Table 6). We
chose these comparisons because we sought to compare the
baseline values with the least symptoms versus the long-
term or 24-month point and at 6 months, when symptoms
tend to be worse, versus the long-term or 24-month point.
The c2 or Fisher exact test was used to compare the per-
centages of shift between the no-NADT and NADT groups.
All analyses were conducted using SAS (SAS Institute,
Cary, NC) at the 2-sided 5% significance level.
Results
The patient characteristics are listed in Table 1. Patients
receiving NADT had worse overall cancer severity and,
consequently, had higher prostate-specific antigen levels,
higher Gleason scores, higher T stages, a greater proportion
of biopsy cores with cancer, and higher rates of pelvic
lymph nodes treated. The sexual domain responses for the
EBRT and BT groups are listed in Tables 2 and 3, respec-
tively. In the sexual domain for the EBRT group, for all
questions, except for “how big a problem has your sexual
function or lack of sexual function been,” a marked sta-
tistically significant difference was found between those
who did or did not receive NADT. The vitality/hormonal
responses for the EBRT and BT groups are listed in
Tables 4 and 5, respectively. In the hormonal/vitality
domain for the EBRT group, patients receiving NADT re-
ported significantly worse responses statistically for the
lack of energy question. Figure 1 shows the 6 statistically
significant question comparisons: frequency of erections,
quality of erections, ability to have an erection, ability to
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Table 1 Patient characteristics
Characteristic
EBRT BT
No NADT (nZ202) NADT (nZ86) P value No NADT (nZ271) NADT (nZ14) P value
Age (y) .03* .57
Median 69 71 66 67
Range 45-83 50-85 45-81 52-79
Age group .07 .88
<60 y 31 (15) 10 (12) 60 (22) 2 (14)
60-69 y 88 (44) 28 (32) 130 (48) 7 (50)
>70 y 83 (41) 48 (56) 81 (30) 5 (36)
Race .87 .34
White 162 (81) 71 (85) 235 (88) 11 (7)
Black 35 (18) 13 (15) 27 (10) 3 (21)
Other 2 (1) 0 (0) 4 (2) 0 (0)
Coexisting illnesses 1.5  1.3 1.4  1.2 .39 1.3  1.1 1.5  1.1 .37
BMI (kg/m2) 28.6  5.3 28.7  5.8 .80 28.4  4.6 28.9  4.8 .76
Prostate size (cm3) 48.9  26.0 51.4  34.3 .83 38.8  17.7 56.7  12.8 <.0001*
PSA (ng/mL) <.0001* .33
Median 5.9 9.1 5.0 6.5
Range 0.5-25.8 1.6-99.3 0.6-26.4 2.1-44
PSA group .0005* .15
<4 ng/mL 36 (18) 11 (13) 59 (22) 4 (29)
4-10 ng/mL 133 (66) 43 (50) 199 (73) 8 (57)
>10 ng/mL 33 (16) 32 (37) 13 (5) 2 (14)
Gleason score <.0001* .18
<7 123 (61) 7 (8) 210 (77) 8 (57)
7 77 (38) 42 (49) 58 (22) 6 (43)
>7 2 (1) 37 (43) 2 (1) 0 (0)
Clinical stage <.0001* .47
T1 157 (78) 45 (52) 228 (84) 11 (79)
T2 45 (22) 41 (48) 42 (16) 3 (21)
Biopsy cores with cancer (%) 0.3  0.2 0.4  0.3 .0001* 0.3  0.2 0.2  0.2 .42
Overall cancer severity <.0001* .07
Low risk 99 (49) 2 (2) 196 (73) 7 (50)
Intermediate risk 97 (48) 33 (39) 70 (26) 6 (43)
High risk 6 (3) 51 (59) 4 (1) 1 (7)
Minimum dose PTV (Gy) .01* NA NA
Median 70 73
Range 48-90 41-77
Maximum dose PTV (Gy) .79 NA NA
Median 80 81
Range 45-107 46-90
IMRT .40 NA NA
Yes 162 (85) 71 (89)
No 29 (15) 9 (11)
Pelvic lymph nodes treated <.0001* NA NA
Yes 7 (4) 25 (31)
No 184 (96) 55 (69)
Prescribed BT dose (Gy) NA NA .77
Median 144 144
Range 80-145 137-145
D90 ETV (Gy) NA NA .51
Median 152 158
Range 12-346 116-178
V100 ETV (%) NA NA .60
Median 93 94
Range 69-100 81-99
Abbreviations: BMI Z body mass index; BT Z brachytherapy; D90 Z radiation dose delivered to 90% of organ; EBRT Z external beam radiation
therapy; ETVZ evaluation target volume, after implantation; IMRTZ intensity modulated radiation therapy; NAZ not applicable; NADTZ neoadjuvant
androgen deprivation therapy; PSAZ prostate-specific antigen; PTVZ planning target volume; V100Z volume receiving 100% of prescription dose.
Data presented as median and range, n (%), or mean  standard deviation.
* Statistically significant.
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reach an orgasm, ability to function sexually, and lack of
energy.
The results of the comparison of the baseline versus
24-month and 6-month versus 24-month percentage of
differences for participants who shifted to a worse dichot-
omized category for a given question are listed in Table 6.
When studying the question, “your ability to reach orgasm
(climax),” 24.4% of the EBRT plus NADT participants
Table 2 External beam radiation therapy only with or without NADT: distribution of participant responses to EPIC sexual HRQOL
items at baseline and 6, 12, and 24 months
How would you rate each
of the following during
the past 4 weeks? NADT n No NADT n
P
value*








Fair þ good þ
very good
.0001y
Baseline 40.5 59.5 84 35.9 64.1 198
6 mo 82.6 17.4 69 45.2 54.8 177
12 mo 77.8 22.2 72 47.1 52.9 170
24 mo 76.1 23.9 67 48.4 51.6 157
How would you describe




















Baseline 37.0 63.0 81 27.2 72.8 191
6 mo 81.4 18.6 70 36.6 63.4 175
12 mo 69.6 30.4 69 37.2 62.8 164
24 mo 68.2 31.8 66 34.0 66.0 159





Never þ less than half the
time wanted þ about
half the time wanted
More than half the time
wanted þ whenever
wanted
Never þ less than half the
time wanted þ about
half the time wanted
More than half
the time wanted þ
whenever wanted
.0001y
Baseline 45.7 54.3 81 43.4 56.6 189
6 mo 87.9 12.1 66 52.1 47.9 169
12 mo 80.6 19.4 67 57.1 42.9 163
24 mo 81.5 18.5 65 59.9 40.1 157











Baseline 34.6 65.4 81 30.4 69.6 194
6 mo 84.1 15.9 69 40.5 59.5 173
12 mo 69.6 30.4 69 43.4 56.6 166
24 mo 65.2 34.9 66 39.1 60.9 156
Overall, how would you




Very poor þ poor Fair þ good þ
very good
Very poor þ poor Fair þ good þ
very good
<.0001y
Baseline 32.5 67.5 83 34.0 66.0 194
6 mo 80.9 19.1 68 43.3 56.7 171
12 mo 74.6 25.4 67 43.4 56.6 168
24 mo 75.4 24.6 65 44.0 56.0 159









No problem þ very
small problem þ
small problem







Baseline 15.5 84.5 84 20.3 79.7 197
6 mo 34.7 65.3 72 29.5 70.5 173
12 mo 25.7 74.3 70 29.0 71.0 169
24 mo 34.9 65.2 66 32.3 67.7 161
Abbreviations: EPIC Z extended prostate cancer index composite; HRQOL Z health-related quality of life; NADT Z neoadjuvant androgen
deprivation therapy.
Data presented as percentages, unless otherwise noted.
* P value reflects a test of the interaction term between group and the time points in linear generalized estimating equations.
y Statistically significant.
Gay et al. International Journal of Radiation Oncology  Biology  Physics308
compared with 13.9% of the EBRT participants shifted
from “fair/good/very good” at baseline to “very poor to
none/poor” at 24 months. Also, a statistically significant
shift to the worse dichotomized category for the question,
“how would you describe the usual quality of your
erections during the last 4 weeks?” and “overall, how
would you rate your ability to function sexually during the
last 4 weeks?” was found between the EBRT plus NADT
group (doing worse) and the EBRT groups for the baseline
versus 24-month comparison. For the baseline versus 24-
Table 3 Brachytherapy distribution only with or without NADTof participant responses to EPIC sexual HRQOL items at baseline and
6, 12, and 24 months
How would you rate
each of the following
during the past 4 weeks? NADT n No NADT n P value*




Fair þ good þ very good Very poor to
none þ poor
Fair þ good þ
very good
.9501
Baseline 35.7 64.3 14 30.5 69.5 262
6 mo 61.5 38.5 13 49.0 51.0 241
12 mo 50.0 50.0 12 46.2 53.8 238
24 mo 58.3 41.7 12 49.6 50.5 222
How would you describe





















Baseline 21.4 78.6 14 20.5 79.5 254
6 mo 53.9 46.2 13 39.4 60.6 236
12 mo 27.3 72.7 11 31.9 68.1 229
24 mo 36.4 63.6 11 36.4 63.6 220





Never þ less than
half the time
wanted þ about half
the time wanted
More than half the time
wanted þ whenever
wanted
Never þ less than
half the time
wanted þ about half
the time wanted




Baseline 35.7 64.3 14 36.4 63.6 253
6 mo 76.9 23.1 13 56.7 43.3 231
12 mo 58.3 41.7 12 53.7 46.3 227
24 mo 66.7 33.3 12 62.0 38.0 216











Baseline 28.6 71.4 14 23.3 76.7 253
6 mo 61.5 38.5 13 42.6 57.5 235
12 mo 36.4 63.6 11 36.1 64.0 233
24 mo 50.0 50.0 12 43.9 56.1 221
Overall, how would you




Very poor + poor Fair + good + very good Very poor + poor Fair + good + very good .5890
Before NADT 35.7 64.3 14 26.9 73.1 260
6 mo 61.5 38.5 13 46.9 53.1 239
12 mo 45.5 55.6 11 42.2 57.8 237
24 mo 41.7 58.3 12 46.1 53.9 219





you during the past
4 weeks?













Baseline 21.4 78.6 14 17.7 82.3 260
6 mo 46.2 53.9 13 33.1 67.0 239
12 mo 45.5 54.6 11 29.0 71.0 238
24 mo 41.7 58.3 12 28.3 71.8 223
Abbreviations: EPIC Z extended prostate cancer index composite; HRQOL Z health-related quality of life; NADT Z neoadjuvant androgen
deprivation therapy.
Data presented as percentages, unless otherwise noted.
* P value reflects a test of the interaction term between group and the time points in linear generalized estimating equations.
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month comparison for the EBRT plus NADT and EBRT
alone groups, no statistically significant shift was found for
the hormone/vitality questions.
When examining the 6- versus 24-month sexual com-
parison (the question, “your ability to have an erection”),
2.3% of the EBRT plus NADT participants and 10.4% of
the EBRT participants shifted from “fair/good/very good”
at 6 months to “very poor to none/poor” at 24 months. Also,
a statistically significant shift was found to the worse
dichotomized category for the questions, “your ability to
reach orgasm (climax)” and “how would you describe the
frequency of your erections during the last 4 weeks” be-
tween the EBRT (doing worse) and EBRT plus NADT
groups for the baseline versus 24-month comparison. For
the 6- versus 24-month comparison for the EBRT plus
NADT and EBRT groups, no statistically significant shift
was found for the hormone/vitality questions.
For both the baseline versus 24-month and the 6- versus
24-month BT plus NADT versus BT alone comparison, no
statistically significant shift was noted for any of the sexual
or hormone/vitality questions. However, the numbers in the
BT plus NADT group were small and insufficient to reach
any meaningful conclusions compared with the BT alone
group.
Discussion
Patients receiving EBRT plus NADT had worse HRQOL,
as measured by the frequency of erections, quality of
erections, ability to have erections, ability to reach orgasm,
ability to function sexually, and lack of energy. However,
when comparing the baseline versus 24-month outcomes,
only the differences in the ability to reach orgasms, quality
Table 4 External beam radiation therapy only with or without NADT: distribution of participant responses to EPIC hormone/vitality
HRQOL items at baseline and 6, 12, and 24 months
Question NADT No NADT
P value*
How big a problem during
the past 4 weeks, if any,

















Baseline 1.2 98.8 84 1.0 99.0 202
6 mo 33.3 66.7 78 2.2 97.8 182
12 mo 20.8 79.2 77 0.5 99.5 181




Baseline 0 100 85 1.5 98.5 201
6 mo 2.6 97.4 78 1.7 98.3 181
12 mo 1.3 98.7 77 1.7 98.3 181
24 mo 2.9 97.1 69 1.2 98.8 167
Depression .8733
Baseline 3.5 96.5 85 6.9 93.1 202
6 mo 3.9 96.2 78 6.1 93.9 181
12 mo 6.5 93.5 77 8.3 91.7 181
24 mo 5.8 94.2 69 4.8 95.2 167
Lack of energy .0003z
Baseline 5.9 94.1 85 13.9 86.1 202
6 mo 35.9 64.1 78 14.9 85.1 181
12 mo 20.8 79.2 77 17.2 82.8 180
24 mo 15.9 84.1 69 16.8 83.2 167
Change in body weight .1251
Baseline 3.6 96.4 84 4.5 95.5 202
6 mo 12.8 87.2 78 3.9 96.1 181
12 mo 14.3 85.7 77 3.9 96.1 179
24 mo 10.1 89.9 69 4.8 95.2 167
Abbreviations: EPIC Z extended prostate cancer index composite; HRQOL Z health-related quality of life; NADT Z neoadjuvant androgen
deprivation therapy.
Data presented as percentages, unless otherwise noted.
* P value reflects a test of the interaction term between group and the time points in linear generalized estimating equations.
y Cochran-Mantel-Haenszel test.
z Statistically significant.
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of erections, and ability to function sexually were signifi-
cant. It is reassuring that patients were not experiencing
worse symptoms at 24 months for most of the sexual and
hormone/vitality questions. This is important, because for
intermediate-risk disease and high-risk disease patients, the
addition of short- and long-term ADT to RT, respectively,
has improved overall and cancer-specific survival in mul-
tiple randomized trials (1-8).
Although the initial report from the PROST-QA trial
provided valuable insights into the HRQOL effect of
radical prostatectomy, BT, or EBRT in prostate cancer
participants (17, 21), surprisingly few data are available on
the long-term adverse effects from NADT on men. A recent
report based on the PROST-QA database reported the
2-month QOL outcomes for 71 participants receiving RT
and NADT (16). In the present study, we included men who
had not received NADT for comparison. Specifically, we
included 202 men who had received EBRT only, 90 who
had received EBRT plus NADT, 286 who had received BT
only, and 20 who had received BT plus NADT. All avail-
able QOL measurement points 24 months were included
for a better understanding of the long-term treatment effects
of NADT. The Medical Research Council RT01 trial, which
delivered 3 to 6 months of NADT plus 64 Gy or 74 Gy in
2-Gy fractions, addressed the short-term effects of NADT
using the University of California, Los Angeles, Prostate
Cancer Index, the Functional Assessment of Cancer
Therapy core questionnaire with its additional prostate
subscale, and the Short-Form 36-item Health Survey
questionnaire (22).
Son et al (23) studied 179 men (72% black) who
completed the EPIC-26 questionnaire at 2, 6, 12, 18, and
24 months after intensity modulated RT and found no sig-
nificant differences in the global score by 24 months, with
Table 5 Brachytherapy only with or without NADT: distribution of participant responses to EPIC hormone/vitality HRQOL items at
baseline and 6, 12, and 24 months
Question NADT No NADT
P value*
How big a problem
during the past
4 weeks, if any, has












very small problem þ
small problem n
Hot flashesy .1014
Baseline 0 100 14 0.7 99.3 270
6 mo 15.4 84.6 13 2.4 97.6 253
12 mo 0 100 12 0.8 99.2 250




Baseline 0 100 14 0.7 99.3 270
6 mo 7.7 92.3 13 1.2 98.8 253
12 mo 0 100 12 0.8 99.2 250
24 mo 0 100 12 0.9 99.1 233
Depressiony .9208
Baseline 0 100 14 4.1 95.9 271
6 mo 15.4 84.6 13 4.3 95.7 254
12 mo 16.7 83.3 12 3.6 96.4 249
24 mo 0 100 12 5.2 94.9 233
Lack of energy .3000
Baseline 7.1 92.9 14 6.7 93.3 270
6 mo 30.8 69.2 13 15.8 84.3 254
12 mo 8.3 91.7 12 14.4 85.6 250




Baseline 0 100 14 3.0 97.1 271
6 mo 30.8 69.2 13 5.9 94.1 254
12 mo 16.7 83.3 12 7.6 92.4 249
24 mo 8.3 91.7 12 6.0 94.0 233
Abbreviations: EPIC Z extended prostate cancer index composite; HRQOL Z health-related quality of life; NADT Z neoadjuvant androgen
deprivation therapy.
Data presented as percentages, unless otherwise noted.
* P value reflects a test of the interaction term between group and the time points in linear generalized estimating equations.
y Cochran-Mantel-Haenszel test.
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How would you describe the FREQUENCY of your erections during the last 4 weeks? (P-value = .0001)
(External Beam Radiotherapy Only +/-NADT)
Never + Less than half the time wanted + About half the time wanted
















 6 months-No NADT
47.9%
52.1%
 12 months-No NADT
42.9%
57.1%
 24 months-No NADT
40.1%
59.9%
How would you describe the usual QUALITY of your erections during the last 4 weeks? (P-value < .0001)
(External Beam Radiotherapy Only +/-NADT)
None at all + Not firm for sexual activity
















 6 months-No NADT
36.6%
63.4%
 12 months-No NADT
37.2%
62.8%





Fig. 1. The 6 statistically significant question comparisons: (A) frequency of erections, (B) quality of erections, (C) ability
to have an erection, (D) ability to reach an orgasm, (E) ability to function sexually, and (F) lack of energy. Abbreviation:
NADT Z neoadjuvant androgen deprivation therapy.
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How would you rate your ability to have an erection during the last 4 weeks? (P-value = .0001)
(External Beam Radiotherapy Only +/-NADT)
















 6 months-No NADT
45.2%
54.8%
 12 months-No NADT
47.1%
52.9%
 24 months-No NADT
48.4%51.6%
How would you rate your ability to reach orgasm (climax) during the last 4 weeks? (P-value < .0001)
(External Beam Radiotherapy Only +/-NADT)
















 6 months-No NADT
40.5%
59.5%
 12 months-No NADT
43.4%
56.6%






Volume 98  Number 2  2017 HRQOL 2 years after RT and short-course NADT 313
Overall, how would you rate your ability to function sexually during the last 4 weeks? (P-value < .0001)
(External Beam Radiotherapy Only +/-NADT)
















 6 months-No NADT
43.3%
56.7%
 12 months-No NADT
43.4%
56.6%
 24 months-No NADT
44.0%
56.0%
How big a problem has 'Lack of Energy' been for you during the last 4 weeks? (P-value = .0003)
(External Beam Radiotherapy Only +/-NADT)
Moderate problem + Big problem
















 6 months-No NADT
14.9%
85.1%
 12 months-No NADT
17.2%
82.8%
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only a statistically significant decline in the frequency of
erections. These differences in findings were likely sec-
ondary to our study’s larger sample size and multicenter
design, leading to a more heterogeneous and generalizable
patient population.
In the European Organization for Research and Treat-
ment of Cancer 22991 trial, randomized intermediate- and
high-risk localized patients to RT or RT and ADT. HRQOL
was assessed with the QLQ-C30 and the QLQ-PR25.
The hormonal treatment symptoms, sexual activity,
and functioning scales were clinically significantly
impaired at 6 months and 1 year, without any marked
difference between the treatment arms from year 2
onward (8).
The results of the present study provide useful insights
for clinicians. Tables 2e6 and Figure 1 could be useful
when counseling patients regarding the side effects from
the different types of RT. Comparing the baseline versus
24-month outcomes, 24%, 23%, and 30% of participants
receiving EBRT plus NADT shifted to the worse
dichotomized category for the ability to reach an orgasm,
quality of erections, and ability to function sexually
compared with 14%, 13%, and 16% in the EBRT group,
respectively. Comparing 6 months versus 24 months, a
Table 6 Comparison of baseline versus 24 months and 6 months versus 24 months for the percentage of participants shifting to the
worst dichotomized category for a given question during the study period
Variable
Baseline vs 24 mo 6 mo vs 24 mo
EBRT BT EBRT BT
NADT
No
NADT P value* NADT
No
NADT P value* NADT
No




Your ability to have an
erection?












25.6 20.3 .32 35.7 21.4 .20 2.3 11.4 .01y 7.1 10.3 >.99
Your ability to reach
orgasm (climax)?
24.4 13.9 .03y 28.6 18.8 .48 1.2 7.9 .03y 7.1 8.9 >.99
Overall, how would you




30.2 16.3 .01y 14.3 18.1 >.99 2.3 7.4 .09 7.1 8.1 >0.99




function been for you
during the past
4 weeks?
18.6 17.8 .87 28.6 15.9 .26 11.6 12.4 .86 14.3 9.6 .64
Hormone/vitality
Hot flashes 5.8 2.0 .13 7.1 0.7 .14 2.3 1.0 .59 0 1.1 >.99
Breast tenderness/
enlargement
2.3 1.0 .59 0 0.7 >.99 1.2 1.0 >.99 0 0.7 >.99
Depression 3.5 3.5 >.99 0 3.7 >.99 2.3 2.5 >.99 0 2.2 >.99
Lack of energy 9.3 9.4 .98 0 7.0 .61 1.2 5.9 .12 0 4.4 >.99
Change in body weight 5.8 3.5 .35 7.1 4.4 .49 7.0 2.5 .09 0 4.1 >.99
Abbreviations: BT Z brachytherapy; EBRT Z external beam radiation therapy; NADT Z neoadjuvant androgen deprivation therapy.
Data presented as percentages, unless otherwise noted.
* c2 or Fisher’s exact test.
y Statistically significant.
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statistically significant improvement was found in the
ability to have an erection, ability to reach an orgasm,
and the frequency of erections, which could be helpful
for reassuring patients at their 6-month follow-up visit.
Because the effects of NADT might be decreasing after
6 months for most patients, these comparisons suggest
that NADT has a greater effect on the ability to have an
erection and the frequency of erections, that both NADT
and EBRT affect the ability to reach an orgasm, and that
EBRT has a greater effect on the ability to function
sexually.
For the hormone/vitality question regarding the lack of
energy, compared with participants receiving EBRT, more
patients receiving EBRT plus NADTwere in a significantly
worse dichotomized category. Although most patients
received 6 months of NADT, these findings were still
evident at 2 years. In general, for this question (Fig. 1F), the
participants who had only received EBRT remained stable,
but those who had received EBRT plus NADT experienced
about a 30% absolute worsening, followed by a 15% ab-
solute improvement at 1 year and a further 5% absolute
improvement at 2 years. The changes over time were not
statistically significant for hot flashes, breast tenderness/
enlargement, depression, or change in body weight. The
power was only 44.4% to detect an effect size of 0.5 using
the sample sizes of 14 participants in the BT plus NADT
group and 271 participants in the BT group with a type I
error of 5%.
One of the potential confounding factors in the present
study was that the length of NADT was not controlled.
However, we limited the length of NADT to 12 months,
and most participants had received 6 months of NADT.
The National Comprehensive Cancer Network prostate
cancer guidelines have suggested considering 4 to
6 months of ADT for intermediate-risk participants un-
dergoing EBRT and 2 to 3 years of ADT for high-risk
participants undergoing EBRT (24). This might explain
why the HRQOL for the entire group reached a nadir at
6 months.
Conclusions
Compared with baseline, at 2 years, the participants
receiving NADT plus EBRT compared with EBRT alone
had worse HRQOL, as measured by the ability to reach
orgasms, quality of erections, and ability to function
sexually. However, no difference was found in the ability
to have an erection, frequency of erections, overall sexual
function, hot flashes, breast tenderness/enlargement,
depression, lack of energy, and change in body weight.
The improved survival in intermediate- and high-risk
patients receiving ADT and EBRT necessitates pretreat-
ment counseling of the HRQOL effects of ADT and
EBRT.
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